Sugi Predict

Sugi Predict / Compounds / Toremifene

Toremifene

Toremifene

SCHEMBL177941

CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1.CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1ESR2

The experimentally established mechanism targets of Toremifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 known ✓ P03372 9/20 0.80
▸ ESR2 known ✓ Q92731 3/20 0.80
▸ LMNA P02545 3/20 0.80
▸ MEN1 O00255 3/20 0.80
▸ TP53 P04637 3/20 0.80
▸ CYP1A2 P05177 3/20 0.80
▸ CYP2D6 P10635 3/20 0.80
▸ KMT2A Q03164 3/20 0.80
▸ KDM4E B2RXH2 2/20 0.80
▸ CYP2C9 P11712 2/20 0.80
▸ MAPK1 P28482 2/20 0.80
▸ CYP3A4 P08684 2/20 0.80
▸ GMNN O75496 1/20 0.80
▸ ALDH1A1 P00352 1/20 0.80
▸ TSHR P16473 1/20 0.80
▸ ALOX12 P18054 1/20 0.80
▸ NFKB1 P19838 1/20 0.80
▸ CYP2C19 P33261 1/20 0.80
▸ THPO P40225 1/20 0.80
▸ HTT P42858 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toremifene SCHEMBL4564 1.00 ESR1 (0.80) ESR1LMNAESR2MEN1TP53
Toremifene SCHEMBL15576158 1.00 ESR1 (0.80) ESR1LMNAESR2MEN1TP53
Toremifene SCHEMBL2367538 1.00 ESR1 (0.80) ESR1LMNAESR2MEN1TP53
Toremifene SCHEMBL30053819 1.00 ESR1 (0.80) ESR1LMNAESR2MEN1TP53
Toremifene SCHEMBL21464516 0.96 ESR1 (0.87) ESR1LMNAESR2MEN1TP53
Toremifene SCHEMBL15865397 0.89 ESR1 (0.67) ESR1LMNAESR2MEN1TP53
Tamoxifen SCHEMBL4019370 0.89 ESR1 (1.00) ESR1LMNAESR2MEN1TP53
Tamoxifen SCHEMBL5328781 0.89 ESR1 (1.00) ESR1LMNAESR2MEN1TP53
Tamoxifen SCHEMBL10336277 0.89 ESR1 (1.00) ESR1LMNAESR2MEN1TP53
Tamoxifen SCHEMBL17164701 0.89 ESR1 (1.00) ESR1LMNAESR2MEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1824 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007149103-A2 VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE KAISER DANIEL E (US) 2007-12-27 — — WO claimed
US-12043667-B2 CLEC12a binding polypeptides and uses thereof INHIBRX BIOSCIENCES, INC. (US) 2024-07-23 — — US disclosed
WO-2023178290-A9 USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES FOUNDATION MEDICINE, INC. (US) 2024-07-18 — — WO disclosed
EP-4399330-A1 GENE FUSIONS IN SARCOMA Foundation Medicine, Inc. (US) 2024-07-17 — — EP disclosed
US-12037385-B2 Anti-polyubiquitin antibodies and methods of use GENENTECH, INC. (US) 2024-07-16 — — US disclosed
US-20240228664-A9 Antibodies Binding to Human PAD4 and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-11 — — US disclosed
US-20240226082-A1 COMBINATION THERAPIES FOR TREATING CANCER TESARO, INC. (US) 2024-07-11 — — US disclosed
US-12030926-B2 Production of heteromultimeric proteins using mammalian cells GENENTECH, INC. (US) 2024-07-09 — — US disclosed
EP-3747464-B1 METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS USING AN ANTI-CD20 ANTIBODY HOFFMANN LA ROCHE (CH) 2024-06-26 — — EP disclosed
CN-118234720-A Radiolabeled fibroblast activation protein ligand 菲罗化学股份公司 2024-06-21 — — CN disclosed
WO-2005058028-A2 NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO GENENTECH, INC. (US) 2005-06-30 — — WO disclosed
US-20050106667-A1 Variant complementary determining regions for use in identifying antigen binding polypeptides; mimetics; direceted protein evolution GENENTECH, INC 2005-05-19 — — US disclosed
US-20050090514-A1 Trp-p8 active compounds and therapeutic treatment methods GENENTECH, INC. 2005-04-28 — — US disclosed
US-20050037431-A1 Methods and compositions for modulating HGF/Met GENENTECH, INC. 2005-02-17 — — US disclosed
WO-2005012531-A2 ANTIBODY CDR POLYPEPTIDE SEQUENCES WITH RESTRICTED DIVERSITY GENENTECH, INC. (US) 2005-02-10 — — WO disclosed
WO-2005003154-A2 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR GENENTECH, INC. (US) 2005-01-13 — — WO disclosed
WO-2005002582-A2 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH, INC. (US) 2005-01-13 — — WO disclosed
EP-1401476-A2 IGF ANTAGONIST PEPTIDES Genentech, Inc. (US) 2004-03-31 — — EP disclosed
US-20030092631-A1 IGF antagonist peptides GENENTECH, INC. 2003-05-15 — — US disclosed
WO-2002072780-A2 IGF ANTAGONIST PEPTIDES GENENTECH, INC. (US) 2002-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090514-A1 Trp-p8 active compounds and therapeutic treatment methods TSG101, TP53, BAX ESR1 2393/4885ESR2 2809/4885LMNA 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.